Edition:
United States

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.97USD
21 Sep 2018
Change (% chg)

$0.06 (+1.02%)
Prev Close
$5.91
Open
$5.91
Day's High
$6.07
Day's Low
$5.66
Volume
205,833
Avg. Vol
97,226
52-wk High
$7.55
52-wk Low
$4.45

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: 1.92
Market Cap(Mil.): $313.42
Shares Outstanding(Mil.): 52.50
Dividend: --
Yield (%): --

Financials

  FOMX.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -2.09 -- --
ROI: -108.73 1.50 12.72
ROE: -109.87 0.19 14.85

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

Sep 11 2018

UPDATE 1-Foamix acne drug meets main goals in late-stage trial, shares surge

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

Sep 11 2018

Foamix Pharma's acne drug meets main goals in late-stage trial

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its drug treating moderate-to-severe acne met the main goals of its third late-stage study.

Sep 11 2018

Earnings vs. Estimates